Banse Heidi, Cribb Alastair E
Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive, Calgary, Alberta T2N 4Z6.
Can Vet J. 2017 Feb;58(2):157-167.
The efficacy of oral phenylbutazone [PBZ; 4.4 mg/kg body weight (BW), q12h], a non-selective non-steroidal anti-inflammatory drug (NSAID), and oral meloxicam (MXM; 0.6 mg/kg BW, q24h), a COX-2 selective NSAID, were evaluated in 2 experimental pain models in horses: the adjustable heart bar shoe (HBS) model, primarily representative of mechanical pain, and the lipopolysaccharide-induced synovitis (SYN) model, primarily representative of inflammatory pain. In the HBS model, PBZ reduced multiple indicators of pain compared with the placebo and MXM. Meloxicam did not reduce indicators of pain relative to the placebo. In the SYN model, MXM and PBZ reduced increases in carpal skin temperature compared to the placebo. Meloxicam reduced lameness scores and lameness-induced changes in head movement compared to the placebo and PBZ. Phenylbutazone reduced lameness-induced change in head movement compared to the placebo. Overall, PBZ was more effective than MXM at reducing pain in the HBS model, while MXM was more effective at reducing pain in the SYN model at the oral doses used.
在马的两种实验性疼痛模型中评估了口服非选择性非甾体抗炎药（NSAID）苯基布他松[PBZ；4.4毫克/千克体重（BW），每12小时一次]和COX-2选择性NSAID美洛昔康（MXM；0.6毫克/千克体重，每24小时一次）的疗效：可调节心脏条带蹄铁（HBS）模型，主要代表机械性疼痛；以及脂多糖诱导的滑膜炎（SYN）模型，主要代表炎性疼痛。在HBS模型中，与安慰剂和MXM相比，PBZ降低了多个疼痛指标。与安慰剂相比，美洛昔康未降低疼痛指标。在SYN模型中，与安慰剂相比，MXM和PBZ降低了腕部皮肤温度的升高。与安慰剂和PBZ相比，美洛昔康降低了跛行评分以及跛行引起的头部运动变化。与安慰剂相比，苯基布他松降低了跛行引起的头部运动变化。总体而言，在所使用的口服剂量下，PBZ在HBS模型中减轻疼痛方面比MXM更有效，而MXM在SYN模型中减轻疼痛方面更有效。
